{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:25Z","timestamp":1792782865959,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidad del Pa\u00eds Vasco","id":[{"id":"https:\/\/ror.org\/000xsnr85","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To analyse the epidemiology, antimicrobial susceptibility and molecular diversity of\n                      <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                      isolates recovered in 2016\u20132017 at a tertiary hospital in northern Spain, and to perform a seven-year pharmacokinetic\/pharmacodynamic (PK\/PD) evaluation using susceptibility data from previous studies conducted in the same hospital setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 231 non-duplicated isolates from 227 patients were studied. Antimicrobial susceptibility was determined by MIC gradient strip tests and molecular typing was performed by NG-MAST v2.0. Epidemiological variables were analysed, and considering the MIC distribution of the isolates, the cumulative fraction of response (CFR) for relevant antimicrobials was estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most infections occurred in men (80.5%), particularly among men who have sex with men (50.3%), with the highest incidence in patients aged 25\u201334 years. All isolates were susceptible to ceftriaxone and cefixime (100%), while susceptibility to azithromycin remained above 95% throughout the study period. In contrast, ciprofloxacin resistance remained high, ranging from 46.2% to 72.7% over the seven-year period. PK\/PD analysis showed that CFR values\u2009\u2265\u200990% were achieved only with cephalosporins. Molecular typing identified 91 STs, including 15 previously undescribed STs. Six genogroups accounted for 51.9% of isolates and were associated with distinct epidemiological and resistance patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ceftriaxone remains the preferred empirical treatment option for gonococcal infection. The favourable PK\/PD performance observed for cefixime supports its activity against the studied isolates, although current treatment recommendations continue to prioritize ceftriaxone, particularly for extragenital infections; whereas ciprofloxacin should not be recommended for empirical use because of persistently high resistance rates. Continued molecular and antimicrobial resistance surveillance is essential for monitoring the emergence and dissemination of NG-MAST genogroups associated with antimicrobial resistance and for guiding future treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10096-026-05591-5","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:07:04Z","timestamp":1783552024000},"page":"3169-3180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular epidemiology and pharmacokinetic\u2013pharmacodynamic analysis of Neisseria gonorrhoeae strains in Northern Spain"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2279-9287","authenticated-orcid":false,"given":"Mar\u00eda del Rosario","family":"Almela-Ferrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3629-3116","authenticated-orcid":false,"given":"Mar\u00eda Carmen","family":"Nieto-Toboso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Montoya-Azpeitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"L\u00f3pez-de Munain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonora","family":"Hern\u00e1ndez-Ragpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5896-6148","authenticated-orcid":false,"given":"Inigo","family":"Gorostiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-6385","authenticated-orcid":false,"given":"Alicia","family":"Rodr\u00edguez-Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-0189","authenticated-orcid":false,"given":"Mikel","family":"Urrutikoetxea-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-9906","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Canut-Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Ibarra-Ugarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-7430","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"D\u00edaz de Tuesta-del Arco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Cisterna-Cancer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3356-004X","authenticated-orcid":false,"given":"Miren","family":"Basaras-Ibarzabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"5591_CR1","unstructured":"World Health Organization Sexually transmitted infections (STIs) [Internet]. Geneva: WHO; [cited 2023 Mar 8]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexually-transmitted-infections-(stis)"},{"issue":"21","key":"5591_CR2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.21.1800264","volume":"23","author":"T Poncin","year":"2017","unstructured":"Poncin T, Fouere S, Braille A, Camelena F, Agsous M, B\u00e9b\u00e9ar C et al (2017) Multidrug-resistant Neisseria gonorrhoeae failing treatment with ceftriaxone and doxycycline in France, November 2017. Euro Surveill 23(21):1800264. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.21.1800264","journal-title":"Euro Surveill"},{"key":"5591_CR3","unstructured":"World Health Organization (2024) Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis and Treponema pallidum (syphilis), and new recommendations on syphilis testing and partner services. Geneva: WHO"},{"key":"5591_CR4","unstructured":"Fifer H, Ismail MA, Soni S, Nwaosu U, Sadiq ST, Milligan A et al (2024) British Association for Sexual Health and HIV national guideline for the management of infection with Neisseria gonorrhoeae"},{"key":"#cr-split#-5591_CR5.1","unstructured":"Unemo M, Ballard R, Ison C, Lewis D, Ndowa F, Peeling R et al (2013) Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus [Internet]. Geneva: World Health Organization"},{"key":"#cr-split#-5591_CR5.2","unstructured":"[cited 2023 Mar 8]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/85343"},{"key":"5591_CR6","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMc1512757","volume":"374","author":"H Fifer","year":"2016","unstructured":"Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D et al (2016) Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med 374:2504\u20132506. https:\/\/doi.org\/10.1056\/NEJMc1512757","journal-title":"N Engl J Med"},{"key":"5591_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1029-2","volume":"15","author":"M Unemo","year":"2015","unstructured":"Unemo M (2015) Current and future antimicrobial treatment of gonorrhoea \u2013 the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis 15:364. https:\/\/doi.org\/10.1186\/s12879-015-1029-2","journal-title":"BMC Infect Dis"},{"issue":"10","key":"5591_CR8","doi-asserted-by":"publisher","first-page":"2300125","DOI":"10.2807\/1560-7917.ES.2023.28.10.2300125","volume":"28","author":"D Golparian","year":"2023","unstructured":"Golparian D, Vestberg N, S\u00f6dersten W, Jacobsson S, Ohnishi M, Fang H et al (2023) Multidrug-resistant Neisseria gonorrhoeae isolate SE690: mosaic penA-60.001 gene causing ceftriaxone resistance internationally has spread to a susceptible genomic lineage, Sweden, September 2022. Euro Surveill 28(10):2300125. https:\/\/doi.org\/10.2807\/1560-7917.ES.2023.28.10.2300125","journal-title":"Euro Surveill"},{"issue":"3","key":"5591_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.05760-11","volume":"56","author":"M Unemo","year":"2012","unstructured":"Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P (2012) High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 56(3):1273\u201380. https:\/\/doi.org\/10.1128\/AAC.05760-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"5591_CR10","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/jac\/dks162","volume":"67","author":"J C\u00e1mara","year":"2012","unstructured":"C\u00e1mara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A et al (2012) Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 67(8):1858\u201360. https:\/\/doi.org\/10.1093\/jac\/dks162","journal-title":"J Antimicrob Chemother"},{"key":"5591_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/22221751.2020.1773325","volume":"9","author":"K Zhou","year":"2020","unstructured":"Zhou K, Chen SC, Yang F, van der Veen S, Yin YP (2020) Impact of the gonococcal FC428 penA allele 60.001 on ceftriaxone resistance and biological fitness. Emerg Microbes Infect 9:1219\u201329. https:\/\/doi.org\/10.1080\/22221751.2020.1773325","journal-title":"Emerg Microbes Infect"},{"key":"5591_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/jac\/dkab390","volume":"77","author":"I Kanesaka","year":"2022","unstructured":"Kanesaka I, Ohno A, Katsuse AK, Takahashi H, Kobayashi I (2022) Emergence of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone by transfer of resistance from an oral Neisseria subflava reservoir. J Antimicrob Chemother 77:364\u2013373. https:\/\/doi.org\/10.1093\/jac\/dkab390","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"5591_CR13","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/S2666-5247(23)00370-1","volume":"5","author":"D Golparian","year":"2024","unstructured":"Golparian D, Cole MJ, S\u00e1nchez-Bus\u00f3 L, Day M, Jacobsson S, Uthayakumaran T et al (2024) Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with 2013 and 2018: a retrospective genomic surveillance study. Lancet Microbe 5(5):e478\u2013e488. https:\/\/doi.org\/10.1016\/S2666-5247(23)00370-1","journal-title":"Lancet Microbe"},{"issue":"6","key":"5591_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/pharmaceutics13060833","volume":"13","author":"A Rodr\u00edguez-Gasc\u00f3n","year":"2021","unstructured":"Rodr\u00edguez-Gasc\u00f3n A, Solin\u00eds M\u00c1, Isla A (2021) The role of PK\/PD analysis in the development and evaluation of antimicrobials. Pharmaceutics 13(6):833. https:\/\/doi.org\/10.3390\/pharmaceutics13060833","journal-title":"Pharmaceutics"},{"key":"5591_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","volume":"21","author":"E As\u00edn-Prieto","year":"2015","unstructured":"As\u00edn-Prieto E, Rodr\u00edguez-Gasc\u00f3n A, Isla A (2015) Applications of pharmacokinetic\/pharmacodynamic analysis of antimicrobial agents. J Infect Chemother 21:319\u2013329. https:\/\/doi.org\/10.1016\/j.jiac.2015.02.001","journal-title":"J Infect Chemother"},{"issue":"10","key":"5591_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101699","volume":"13","author":"R Alonso","year":"2021","unstructured":"Alonso R, Rodr\u00edguez-Achaerandio A, Aguirre-Qui\u00f1onero A, Artetxe A, Mart\u00ednez-Ballesteros I, Rodr\u00edguez-Gasc\u00f3n A et al (2021) Molecular epidemiology, antimicrobial surveillance, and PK\/PD analysis to guide the treatment of Neisseria gonorrhoeae infections. Pharmaceutics 13(10):1699. https:\/\/doi.org\/10.3390\/pharmaceutics13101699","journal-title":"Pharmaceutics"},{"issue":"2","key":"5591_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.eimc.2019.05.002","volume":"38","author":"U Ibargoyen Garc\u00eda","year":"2020","unstructured":"Ibargoyen Garc\u00eda U, Nieto Toboso MC, Azpeitia EM, Imaz P\u00e9rez M, Hern\u00e1ndez Ragpa L, \u00c1lava Menica JA et al (2020) Epidemiological surveillance study of gonococcal infection in northern Spain. Enferm Infecc Microbiol Clin 38(2):59\u201364. https:\/\/doi.org\/10.1016\/j.eimc.2019.05.002","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"5591_CR18","unstructured":"Clinical and Laboratory Standards Institute (2024) Performance standards for antimicrobial susceptibility testing. 34th ed. CLSI supplement M100. Wayne: CLSI"},{"key":"5591_CR19","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0 [Internet] (2024) Available from: http:\/\/www.eucast.org"},{"key":"5591_CR20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1128\/AAC.36.5.993","volume":"36","author":"JT Lettieri","year":"1992","unstructured":"Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH (1992) Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 36:993\u2013996. https:\/\/doi.org\/10.1128\/AAC.36.5.993","journal-title":"Antimicrob Agents Chemother"},{"key":"5591_CR21","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.clinthera.2010.04.003","volume":"32","author":"P Koomanachai","year":"2010","unstructured":"Koomanachai P, Bulik CC, Kuti JL, Nicolau DP (2010) Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 32:766\u2013779. https:\/\/doi.org\/10.1016\/j.clinthera.2010.04.003","journal-title":"Clin Ther"},{"key":"5591_CR22","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1128\/AAC.02430-12","volume":"57","author":"TP Dumitrescu","year":"2013","unstructured":"Dumitrescu TP, Anic-Milic T, Oreskovic K, Padovan J, Brouwer KL, Zuo P et al (2013) Development of a population pharmacokinetic model to describe azithromycin concentrations. Antimicrob Agents Chemother 57:3194\u20133201. https:\/\/doi.org\/10.1128\/AAC.02430-12","journal-title":"Antimicrob Agents Chemother"},{"key":"5591_CR23","doi-asserted-by":"publisher","first-page":"e01409","DOI":"10.1128\/AAC.01409-17","volume":"62","author":"M Soda","year":"2017","unstructured":"Soda M, Ito S, Matsumaru N, Nakamura S, Nagase I, Takahashi H et al (2017) Evaluation of the microbiological efficacy of azithromycin using PK simulation. Antimicrob Agents Chemother 62:e01409\u2013e01417. https:\/\/doi.org\/10.1128\/AAC.01409-17","journal-title":"Antimicrob Agents Chemother"},{"key":"5591_CR24","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/jac\/dkq289","volume":"65","author":"SA Chisholm","year":"2010","unstructured":"Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM (2010) Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 65:2141\u20132148. https:\/\/doi.org\/10.1093\/jac\/dkq289","journal-title":"J Antimicrob Chemother"},{"key":"5591_CR25","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1086\/383047","volume":"189","author":"IM Martin","year":"2004","unstructured":"Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG (2004) Rapid sequence-based identification of gonococcal transmission clusters. J Infect Dis 189:1497\u20131505. https:\/\/doi.org\/10.1086\/383047","journal-title":"J Infect Dis"},{"issue":"3","key":"5591_CR26","doi-asserted-by":"publisher","first-page":"20358","DOI":"10.2807\/ese.18.03.20358-en","volume":"18","author":"SA Chisholm","year":"2013","unstructured":"Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA et al (2013) Molecular epidemiological typing within Euro-GASP reveals predominance of a multidrug-resistant clone. Euro Surveill 18(3):20358. https:\/\/doi.org\/10.2807\/ese.18.03.20358-en","journal-title":"Euro Surveill"},{"key":"5591_CR27","volume-title":"Gonorrhoea. Annual epidemiological report for 2017","author":"European Centre for Disease Prevention and Control","year":"2019","unstructured":"European Centre for Disease Prevention and Control (2019) Gonorrhoea. Annual epidemiological report for 2017. ECDC, Stockholm"},{"key":"5591_CR28","volume-title":"Gonorrhoea. Annual epidemiological report for 2023","author":"European Centre for Disease Prevention and Control","year":"2025","unstructured":"European Centre for Disease Prevention and Control (2025) Gonorrhoea. Annual epidemiological report for 2023. ECDC, Stockholm"},{"issue":"3","key":"5591_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.eimce.2024.06.012","volume":"43","author":"A Cumplido","year":"2025","unstructured":"Cumplido A, Aramburu J, Font M, Montes M, Abad R, L\u00f3pez E et al (2025) Antimicrobial resistance and epidemiology of Neisseria gonorrhoeae in Lleida, Spain, 2017\u20132024. Enferm Infecc Microbiol Clin 43(3):156\u2013161. https:\/\/doi.org\/10.1016\/j.eimce.2024.06.012","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"7","key":"5591_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s10096-023-04601-0","volume":"42","author":"M Herrero","year":"2023","unstructured":"Herrero M, Broner S, Cruells A, Esteve S, Ferr\u00e9 L, Mendioroz J et al (2023) Epidemiology and antimicrobial resistance of Neisseria gonorrhoeae in Catalonia, Spain, 2016\u20132019. Eur J Clin Microbiol Infect Dis 42(7):883\u2013893. https:\/\/doi.org\/10.1007\/s10096-023-04601-0","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5591_CR31","doi-asserted-by":"publisher","first-page":"e0271657","DOI":"10.1371\/journal.pone.0271657","volume":"17","author":"N Nokchan","year":"2022","unstructured":"Nokchan N, Wongsurawat T, Jenjaroenpun P, Nitayanon P, Tribuddharat C (2022) Whole-genome sequence analysis of resistant Neisseria gonorrhoeae. PLoS ONE 17:e0271657. https:\/\/doi.org\/10.1371\/journal.pone.0271657","journal-title":"PLoS ONE"},{"key":"5591_CR32","doi-asserted-by":"publisher","first-page":"101318","DOI":"10.1016\/j.lanepe.2025.101318","volume":"54","author":"S Jacobsson","year":"2025","unstructured":"Jacobsson S, Cole MJ, Schr\u00f6der D, van Jansen M, Day M, K\u00f6dm\u00f6n C et al (2025) Antimicrobial resistance in Neisseria gonorrhoeae in Europe in 2022. Lancet Reg Health Eur 54:101318. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101318","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"5591_CR33","doi-asserted-by":"publisher","first-page":"2500965","DOI":"10.2807\/1560-7917.ES.2026.31.2.2500965","volume":"31","author":"S Jacobsson","year":"2026","unstructured":"Jacobsson S, Cole MJ, van Jansen M, Schr\u00f6der D, M\u00e5rdh O, K\u00f6dm\u00f6n C et al (2026) High prevalence of tetracycline resistance in Neisseria gonorrhoeae across Europe, 2024. Euro Surveill 31(2):2500965. https:\/\/doi.org\/10.2807\/1560-7917.ES.2026.31.2.2500965","journal-title":"Euro Surveill"},{"issue":"1","key":"5591_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05931-0","volume":"21","author":"S Jacobsson","year":"2021","unstructured":"Jacobsson S, Cole MJ, Spiteri G, Day M, Unemo M, Euro-GASP Network (2021) Associations between antimicrobial susceptibility\/resistance of Neisseria gonorrhoeae isolates in European Union\/European Economic Area and patients\u2019 gender, sexual orientation and anatomical site of infection, 2009\u20132016. BMC Infect Dis 21(1):273. https:\/\/doi.org\/10.1186\/s12879-021-05931-0","journal-title":"BMC Infect Dis"},{"key":"5591_CR35","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/OLQ.0000000000000185","volume":"41","author":"MJ Cole","year":"2014","unstructured":"Cole MJ, Spiteri G, Town K, Unemo M, Hoffmann S, Chisholm SA et al (2014) Risk factors for antimicrobial-resistant Neisseria gonorrhoeae in Europe. Sex Transm Dis 41:723\u20139. https:\/\/doi.org\/10.1097\/OLQ.0000000000000185","journal-title":"Sex Transm Dis"},{"issue":"5","key":"5591_CR36","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/jac\/dkaf109","volume":"80","author":"H Fifer","year":"2025","unstructured":"Fifer H, Johnson A (2025) The continuing evolution of antibiotic resistance in Neisseria gonorrhoeae. J Antimicrob Chemother 80(5):1213\u20131219. https:\/\/doi.org\/10.1093\/jac\/dkaf109","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"5591_CR37","first-page":"1","volume":"70","author":"Centers for Disease Control and Prevention","year":"2021","unstructured":"Centers for Disease Control and Prevention (2021) Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 70(4):1\u2013187","journal-title":"MMWR Recomm Rep"},{"key":"5591_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12879-023-08938-x","volume":"24","author":"J Zhong","year":"2024","unstructured":"Zhong J, Le W, Li X, Su X (2024) PK\/PD analysis of antibiotics against Neisseria gonorrhoeae. BMC Infect Dis 24:104. https:\/\/doi.org\/10.1186\/s12879-023-08938-x","journal-title":"BMC Infect Dis"},{"key":"5591_CR39","doi-asserted-by":"publisher","first-page":"e064782","DOI":"10.1136\/bmjopen-2022-064782","volume":"12","author":"FYS Kong","year":"2022","unstructured":"Kong FYS, Unemo M, Lim SH et al (2022) Optimisation of treatments for oral Neisseria gonorrhoeae infection: STI-PK study protocol. BMJ Open 12:e064782. https:\/\/doi.org\/10.1136\/bmjopen-2022-064782","journal-title":"BMJ Open"},{"issue":"41","key":"5591_CR40","doi-asserted-by":"publisher","first-page":"1900648","DOI":"10.2807\/1560-7917.ES.2020.25.41.1900648","volume":"25","author":"S Banhart","year":"2020","unstructured":"Banhart S, Jansen K, Buder S et al (2020) Molecular epidemiological typing of Neisseria gonorrhoeae and decreased susceptibility to cefixime. Euro Surveill 25(41):1900648. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.41.1900648","journal-title":"Euro Surveill"},{"key":"5591_CR41","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1017\/S095026881900150X","volume":"147","author":"MD Guerrero-Torres","year":"2019","unstructured":"Guerrero-Torres MD, Men\u00e9ndez MB, Guerras CS et al (2019) Epidemiology and antimicrobial susceptibility of Neisseria gonorrhoeae in Madrid, 2016. Epidemiol Infect 147:e274. https:\/\/doi.org\/10.1017\/S095026881900150X","journal-title":"Epidemiol Infect"},{"issue":"3","key":"5591_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/mdr.2021.0483","volume":"29","author":"A Carannante","year":"2023","unstructured":"Carannante A, Vacca P, Fontana S et al (2023) Seven years of Neisseria gonorrhoeae culture collection: antimicrobial resistance and molecular epidemiology. Microb Drug Resist 29(3):85\u201395. https:\/\/doi.org\/10.1089\/mdr.2021.0483","journal-title":"Microb Drug Resist"},{"issue":"6","key":"5591_CR43","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S2666-5247(22)00044-1","volume":"3","author":"L S\u00e1nchez-Bus\u00f3","year":"2022","unstructured":"S\u00e1nchez-Bus\u00f3 L, Cole MJ, Spiteri G, Day M, Jacobsson S, Golparian D et al (2022) Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study. Lancet Microbe 3(6):e452\u2013e463. https:\/\/doi.org\/10.1016\/S2666-5247(22)00044-1","journal-title":"Lancet Microbe"},{"issue":"7","key":"5591_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1473-3099(18)30225-1","volume":"18","author":"SR Harris","year":"2018","unstructured":"Harris SR, Cole MJ, Spiteri G, S\u00e1nchez-Bus\u00f3 L, Golparian D, Jacobsson S et al (2018) Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey. Lancet Infect Dis 18(7):758\u2013768. https:\/\/doi.org\/10.1016\/S1473-3099(18)30225-1","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"5591_CR45","doi-asserted-by":"publisher","first-page":"10499","DOI":"10.3390\/ijms231810499","volume":"23","author":"B M\u0142ynarczyk-Bonikowska","year":"2022","unstructured":"M\u0142ynarczyk-Bonikowska B, Kowalewski C, Kr\u00f3lak-Uli\u0144ska A, Marusza W (2022) Molecular mechanisms of drug resistance and epidemiology of multidrug-resistant variants of Neisseria gonorrhoeae. Int J Mol Sci 23(18):10499. https:\/\/doi.org\/10.3390\/ijms231810499","journal-title":"Int J Mol Sci"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05591-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05591-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05591-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:02:34Z","timestamp":1792281754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05591-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5591"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05591-5","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Clinical Research Ethics Committee of Basurto University Hospital (internal code: 48.18CEICHUB). All procedures performed in this study were conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the Ethics Committee due to the retrospective observational design of the study and the use of anonymised clinical and microbiological data.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}